Lexicon’s anti-diabetic drug positively clears phase IIb trials

27 June 2012, Washington(Zeepharmacy.com) A SGLT1/SGLT2 (sodium and glucose transporter type 1 and 2) inhibitor medication manufactured by Lexicon Pharmaceuticals is shown to cause promising phase IIb clinical trial outcome, which is developed for treating Type 2 resistant diabetes. The clinical investigators of the study claimed that the results obtained from the drug code named LX4211 are statistically significant for reducing blood sugar levels along with showing promising results in alleviation of high blood pressure levels as well as weight issues. The pill is believed to function as an exceptional dual inhibitor with the aid of the combined action on SGLT1 and SGLT2 transporters. LX4211 alleviates the quantity of the glucose that from the gastrointestinal tract to the bloodstream through the inhibition activity of SGLT1, which functions as a vital glucose transporter responsible for its absorption. Whereas, SGLT2 plays a key role in increasing the quantity of the glucose excreted in the urine by acting as a transporter for glucose reabsorption from the kidneys. The study was carried by the investigators of Woodland’s Biotech company, who claimed that the solid score results were obtained from the phase IIb study of dose-escalation and are planning to do phase III trials in early next year. It has been previously proved that the inhibition of SGLT1 by the LX4211 drug molecule results in an increase in GI hormones namely GLP-1 and PYY that are related to appetite and glycemic control. Dr. Brian Zambrowicz, chief scientific officer of Lexicon Pharmaceuticals said that the striking results obtained by the LX4211 drug aid in differentiating this drug from the current pipeline drugs related to Type 2 diabetes treatment, all of which belong to SGLT2-selective inhibitor class of drugs. He further added that a superior blood sugar control as well as the positive safety profile of the drug is attributed to the dual action mechanism of the drug. For more: http://www.zeepharmacy.com/kamagra-jelly.html Zeepharmacy.com 1600 Pennsylvania Ave, Washington, DC, USA – 20002

Suggested Articles

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.

A new study shows how circular ecDNA outside of the chromosome in cancer cells drives oncogenes, making tumors more aggressive.

The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.